A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1060-1067

  Yada, A ^a   Yazawa, M ^a   Ishida, S ^a   Yoshida, H ^a   Ichikawa, K ^a   Kurakata, S ^a   Fujiwara, Kosaku ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Apoptosis; Combination therapy; Death receptor 5; Humanized antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CS 1008; DEATH RECEPTOR 5; DOCETAXEL; GEMCITABINE; LIPOCORTIN 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL;

EID: 44849120686     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn015     Document Type: Article

References (29)

1. Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 2005; 21: 35-56.
2. Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily [review]. Nat Rev Cancer 2002; 2: 420-430.
3. Hymowitz SG, Christinger HW, Fuh G et al. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571.
4. Sprick MR, Weigand MA, Rieser E et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
5. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
6. Georgakis GV, Li Y, Humphreys R et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130: 501-510.
7. McCarthy MM, DiVito KA, Sznol M et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006; 12: 3856-3863.
8. Younes M, Georgakis GV, Rahmani M et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006; 42: 542-547.
9. Daniels RA, Turley H, Kimberley FC et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005; 15: 430-438.
10. Spierings DC, de Vries EG, Vellenga E et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52: 821-831.
11. Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Mad 2001; 7: 383-385.
12. Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hapatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
13. Buchsbaum DJ, Zhou T, Grizzle WE et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9: 3731-3741.
14. Straughn JM Jr, Oliver PG, Zhou T et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006; 101: 46-54.
15. Mori E, Thomas M, Mortoki K et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004; 11: 203-207.
16. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: Research0034.1-0034.11.
17. Gavin A, Hulett M, Hogarth PM. Molecular basis for the interaction of Fc receptors with immunoglobulins. In van de Winkel JGJ, Hosarth PM (eds): The Immunoglobulin Receptors and Their Physiological and Pathological Roles in Immunity. London, UK: Kluwer Academic Publishers 1998; 11-35.
18. Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92: 1430-1441.
19. Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. Drug Resist Updat 2004; 7: 345-358.
20. Kim HS, Lee JW, Soung YH et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003; 125: 708-715.
21. Peng H, Huang Y, Duan Z et al. Cellular IAP1 regulates TRAIL-induced apopitosis in human fetal cortical neural progenitor cells. J Neurosci Res 2005; 82: 295-305.
22. Wang P, Song JH, Song DK et al. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signal 2006: 18: 1528-1535.
23. Chawla-Sarkar M, Bae SI, Reu FJ et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004: 11: 915-923.
24. LeBlanc H, Lawrence D, Varfolomeev E et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002: 8: 274-281.
25. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005; 62: 165-186.
26. Lacour S, Micheau O, Hammann A et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003; 22: 1807-1816.
27. Wu XX, Kakehi Y, Mizutani Y et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003; 104: 409-417.
28. Ohtsuka T, Buchsbaum D, Oliver P et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and milochondrial death pathway. Oncogene 2003; 22: 2034-2044.
29. Hylander BL, Pitoniak R, Penetrante RB et al. The anti-tumor effect of Apo2L/TRAIL on patent pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Mad 2005; 3: 22.